The European Medicines Agency’s human medicines committee (CHMP) has recommended granting an extension of indication for the Pfizer/BioNTech COVID-19 vaccine to include use in children aged 5 to 11.
Korean company, SK, is investing in the Philadelphia-based Center for Breakthrough Medicines (CBM), a move that will support the US company in its bid to become the world's largest end-to-end cell and gene therapy contract development and manufacturing...
GreenLight Biosciences and CDMO Samsung Biologics have announced a partnership agreement, with Samsung Biologics to manufacture GreenLight’s messenger RNA COVID-19 vaccine candidate at commercial scale.
A new clinical trial of heterologous – or ‘mix-and-match’ – combinations of COVID-19 vaccines is set to start in Pakistan: seeking to add to research on the effectiveness of such combinations.
Vaccibody, a Norway-based pioneer in the neoantigen cancer vaccine space, has changed its name to Nykode Therapeutics, and has entered into a license and collaboration agreement with US company, Regeneron, to develop vaccines against cancer and infectious...
A centralized testing approach, developed by the Coalition for Epidemic Preparedness Innovations (CEPI) and used by more than 30 COVID-19 vaccine developers, will be expanded to create a standardized evaluation model for other epidemic and pandemic disease...
The US Food and Drug Administration (FDA) has amended the emergency use authorizations (EUA) for Pfizer/BioNTech and Moderna COVID-19 vaccines: authorizing the use of a booster shot for all individuals aged 18+.
Emulate, Inc recently launched the Zoë-CM2 Culture Module, a second-generation Zoë instrument core to its ‘Organ-on-a-Chip’ based Human Emulation System.
Biogen says it is disappointed with feedback received from a European Medicines Agency committee on its aducanumab Marketing Authorization Application: but pledges to continue to engage with the regulator as it considers its next steps.
The COVID-19 pandemic has triggered a surge in investment at providers of bioprocess consumables, with companies including Danaher and Thermo Fisher Scientific spending quickly to meet demand for single-use systems and other technologies.
The vacuum filtration units are suitable for lab-based research in low volumes, with the company stating the update improves speed, capacity, and stability.
The company will increase its production capacity for media, buffers, and other process liquids to meet the surge in demand that occurred alongside the pandemic.
To further support the increasing number of pharma companies investing in microbials, Lonza is expanding its microbial development laboratories at its Visp, Switzerland site by 50%.
EIT Health and Biogen have launched the ‘neurotechprize’ to help develop promising technology from all over the world that looks to address Alzheimer’s disease (AD).
CRISPR Therapeutics and ViaCyte, Inc. have received the green light from Health Canada for their Clinical Trial Application for VCTX210: an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes (T1D)....
Australian biotech researchers and entrepreneurs are being encouraged to apply for funding from the country’s first national biotech incubator, CUREator.
The race is on: Eli Lilly has begun the application for the approval of its Alzheimer's disease (AD) treatment in the US, potentially setting it up against rival Biogen's recently approved Aduhelm.
Pfizer and BioNTech have completed long-range drone deliveries of their mRNA COVID-19 vaccine: with partner Zipline claiming to be the first to deliver vaccines in this way at a national scale.
The Cell and Gene Therapy Catapult and Deep Science Ventures have formed a partnership aimed at creating innovative approaches to address barriers in the Advanced Therapy Medicinal Products (ATMP) industry.
Johnson & Johnson has announced its intent to separate its Consumer Health business into a new publicly traded company: allowing J&J to put a sharpened focus on pharmaceuticals and medical devices.
Be the Match BioTherapies (BTMB) says it is critical that resilient cell sourcing infrastructures exist when cell and gene therapies (CGT) surge to market.
Culture Biosciences, a company enabling biotech firms to develop and scale manufacturing processes in the cloud, recently announced an $80m Series B round, taking the funds it has raised to date to $100m+.
The infusion of funds in the Halle/Westfalen, Germany manufacturing complex is intended to help meet growing global demand for injectable pharmaceuticals.
A new specialized lab, office and collaboration space for over 100 life science and health technology professionals, entrepreneurs, and researchers was recently announced for The Campus, Cherrywood in South Dublin, Ireland.
Dutch stem cell company Neuroplast has announced positive Phase 1 results for its Neuro-Cells investigational stem cell treatment in patients suffering from Traumatic Spinal Cord Injury (TSCI).
The COVID-19 pandemic has reversed years of global progress in tackling tuberculosis and - for the first time in over a decade - TB deaths have increased. Research breakthroughs – such as new vaccines – are needed to rapidly reduce the number of new cases...
Novavax has completed its rolling submission to the World Health Organization for emergency use listing (EUL) of NVX-CoV2373, its COVID-19 vaccine candidate.
Waters Corporation and Sartorius are partnering with the aim of providing bioprocess experts with direct access to high-quality mass spectrometry (MS) data to accelerate the speed and improve the accuracy of biopharmaceutical process development.
bluebird bio has signed a long-term lease for a 61,000 square foot facility at Assembly Row, Greater Boston: saying the new headquarters has been designed to reflect modern ways of working and deliver significant cost savings.
CEPI, the Coalition for Epidemic Preparedness Innovations, has announced the first funding awards under a $200m program to advance development of vaccines against SARS-CoV-2 variants and other betacoronaviruses.
Sphere Fluidics, a UK company that has developed and is commercializing single cell analysis systems underpinned by its picodroplet technology, has just closed a US$40m investment round.
Biomunex Pharmaceuticals, a French company focused on the discovery and development of bi- and multi-specific antibodies, sees its BiXAb5 project receive nearly €3m (US$3.5m) in the form of a grant from the French government.